1. Home
  2. APLT vs LOAN Comparison

APLT vs LOAN Comparison

Compare APLT & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLT
  • LOAN
  • Stock Information
  • Founded
  • APLT 2016
  • LOAN 1989
  • Country
  • APLT United States
  • LOAN United States
  • Employees
  • APLT N/A
  • LOAN N/A
  • Industry
  • APLT Biotechnology: Pharmaceutical Preparations
  • LOAN Real Estate Investment Trusts
  • Sector
  • APLT Health Care
  • LOAN Real Estate
  • Exchange
  • APLT Nasdaq
  • LOAN Nasdaq
  • Market Cap
  • APLT 63.6M
  • LOAN 61.5M
  • IPO Year
  • APLT 2019
  • LOAN 1999
  • Fundamental
  • Price
  • APLT $0.42
  • LOAN $5.36
  • Analyst Decision
  • APLT Buy
  • LOAN
  • Analyst Count
  • APLT 6
  • LOAN 0
  • Target Price
  • APLT $6.10
  • LOAN N/A
  • AVG Volume (30 Days)
  • APLT 883.6K
  • LOAN 20.4K
  • Earning Date
  • APLT 11-06-2025
  • LOAN 10-22-2025
  • Dividend Yield
  • APLT N/A
  • LOAN 8.58%
  • EPS Growth
  • APLT N/A
  • LOAN N/A
  • EPS
  • APLT N/A
  • LOAN 0.48
  • Revenue
  • APLT $121,000.00
  • LOAN $7,300,469.00
  • Revenue This Year
  • APLT N/A
  • LOAN N/A
  • Revenue Next Year
  • APLT $5,931.24
  • LOAN $4.47
  • P/E Ratio
  • APLT N/A
  • LOAN $11.17
  • Revenue Growth
  • APLT N/A
  • LOAN N/A
  • 52 Week Low
  • APLT $0.30
  • LOAN $4.74
  • 52 Week High
  • APLT $10.62
  • LOAN $6.05
  • Technical
  • Relative Strength Index (RSI)
  • APLT 38.92
  • LOAN 47.86
  • Support Level
  • APLT $0.43
  • LOAN $5.30
  • Resistance Level
  • APLT $0.46
  • LOAN $5.44
  • Average True Range (ATR)
  • APLT 0.03
  • LOAN 0.11
  • MACD
  • APLT -0.01
  • LOAN 0.00
  • Stochastic Oscillator
  • APLT 0.35
  • LOAN 71.43

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

Share on Social Networks: